Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As an EOLS shareholder you should be absolutely terrified. You were and are a FUDster. The problem was Foley's mismanagement—not Daxxify the product.
Many of us have made a lot of money over the years long RVNC—you just had to pick the right times to trade it. I'm certainly disappointed with the low buyout price, but having just done a very large buy in June at $2.80 I'm not that disappointed.
This is good news for those of us who aggressively added shares in the $2's. Not great news for the jbogs of the world.
Regardless, it's another epic fail by Foley because Daxxify is worth much more. There's a decent chance a better bid will emerge so I'm holding my shares for now.
Unbelievable! I'm not sure if I'm more thrilled with the revised numbers or disappointed that they couldn't even get those numbers right in the press release. It makes you wonder if they're just making the numbers up.
Mark doesn't know how many accounts have ordered Daxxify!! 🤦🏻♂️
He just said on the call that it was 3000 at the end of Q1 but their Q1 press release clearly stated 3500.
That is the difference between 200 and 700 accounts added in Q2.
Mark just said reorders made up 3/4 of aesthetics Daxxify orders in Q2. It's odd that wasn't included in the press release. It's disappointing that they only added 200 Daxxify accounts in the quarter, but on the flip side that makes the unit growth more impressive.
I think what Mark said was true in that prices are trending down and I've definitely been seeing more practices offering Daxxify at $5-$8/unit recently. As soma2022 has informed us practices can get Daxxify at $2.75/unit if they're doing sufficient volume—which of course any self-respecting practice not run by an unscrupulous CosmeticMD should be. But in typical Foley fashion he may have overstated somewhat how close they are to price parity. Admittedly the majority of practices that advertise Daxxify on social media don't include their price so the sample size is small but it seems to be a fairly good cross-section of practices that do.
For reference the first screenshot below shows a practice with total price parity based on the amount of toxin. You get the exact same amount of toxin for the same price. (2:1 Daxxify to Botox, 3:1 Dysport to Botox unit conversation). Below that are some recent posts showing significantly higher Daxxify unit prices. Some don't show their prices for other toxins but at $15/unit it's hard to imagine Daxxify isn't considerably higher than their other toxins (Botox would have to be $30/unit for parity). Confusingly some practices advertise a flat price for any toxin as seen in the last screenshot. When that includes Dysport the practice is pretty clearly obfuscating the real units to simplify things for the customer (or to cheat them), but many don't include Dysport which makes it less clear without a phone call.
Another problem right now is that many if not most practices are still charging a considerable premium for Daxxify over Botox (on a 2-to-1 unit basis). Partly this is a remnant of Revance's failed premium price strategy—but it's also the result of many greedy CosmeticMDs not wanting to see their customers (I call them customers not patients as these doctors are unscrupulous salespeople more than medical professionals) less often without being compensated by a higher price. Daxxify market share will thus have to be won by better practices offering the best products to their customers at a fair price taking share from unscrupulous practices that do not.
What was the incorrect information? Can you post a screenshot?
Skincare Company Galderma Sees Opportunity in ‘Ozempic Face’
"As such injections go mainstream, one wrinkle Galderma could find is competition. The Swiss company is the No. 2 player globally in the segment behind AbbVie, but the rapid growth of the market has attracted new entrants that could erode its market share, analysts at UBS said in a note."
https://www.wsj.com/business/skincare-company-galderma-sees-opportunity-in-ozempic-face-6f2d6738
Agreed. Except RVNC is weak today mostly because the U.S. 10-Y is up 15 bp on the stronger than expected payroll print. Although I'm sure some clowns that post here would like everyone to believe it's because Daxxify "doesn't work."
What does Revance's share price have to do with Evolus' CEO exercising options not expiring for years and dumping them on the open market?
EOLS CEO David Moatazedi just exercised options for over 330,000 shares not expiring until 2028 and 2032, and then immediately sold them LOL. That's quite the surprise because I heard from @boraborak38 that double-dose Jeuveau is just as good as Daxxify. 😂
Money losing companies with significant debt and no clear trajectory to reach breakeven before they run out of cash. There's many of them. The assumption is that these companies will eventually be unable to raise more cash and go bankrupt. Many will. Most of these companies didn't even exist before the ZIRP era and have never had to face an environment like this. Foley has totally mismanaged capital allocation. The shotgun share sale earlier this year after saying they were funded to breakeven only increased investor distrust in management.
Despite Foley's follies there's only so long that unscrupulous CosmeticMDs can hide the fact that they're giving their patients inferior products. The biggest risk to Daxxify is that a truly better toxin (not a gimmick like double dose Jeuveau) emerges in the next few years.
What's the largest stock in the Russell 2000? Why don't you look it up and check their revenue growth. That's a moronic comparison. This market has punished money losers and rewarded money makers. If you believe CosmeticMD that Daxxify "doesn't work" then what are you still doing here? I'm not recommending you or anybody else to buy or not buy the stock. The fact remains that Daxxify is the best toxin on the market and CosmeticMD is a proven liar.
Is this what you call "laying out the bear case" ...
This post was deleted, not sure if by the mods or by the degenerate doctor himself. Why would an actual doctor put so much effort into spreading lies about Daxxify? To many people here the answer is patently obvious.
In my opinion Foley's biggest folly was thinking the industry would welcome a better product with open arms. Foley failed to anticipate and properly plan for the inevitable backlash from the existing large and well funded players and their unscrupulous CosmeticMD stooges.
We can expect a new screed from the doctor today.
The market obviously doesn't believe they can hit the guidance. The current trajectory makes it look pretty difficult. I'm skeptical they can do it. I'm concerned that a recession could derail their progress, although there's an argument to be made that Revance could gain more share in such a scenario as their products offer better value. Regardless, despite what the clown accounts on this board (the ones who will likely tag this post with a clown emoji) want you to believe, Daxxify is by far the best toxin currently on the market. It's likely we will see more of an S-curve pickup in adoption as more people become aware of Daxxify's superiority. Obviously there are a lot of people who want to prevent that. Some post right here on this board. The biggest risk to Revance's long term success is that an even better toxin emerges, and Foley's stumbles have cost them a lot of time to grow large enough to survive that.
A bet on RVNC stock now is mainly a bet on whether a better toxin will come to market before Revance can fix their balance sheet. There is also a growing risk that CosmeticMD's benefactors will start a damaging price war as their market share declines. However, Daxxify will continue to take share from the existing toxins. That's inevitable. As noted by an analyst on the call, Daxxify ranks last in awareness—but the buzz on social media has been growing. Daxxify is simply a better product and also a better name than Jeuveau—although I expect both to continue to gain share from Botox for now.
I expect RVNC to remain highly sensitive to interest rates until there's more evidence that their guidance will be met. Expectations have certainly been reset now, so if Revance can just meet or exceed their guidance for revenue and expenses for 2024 I expect the stock to be considerably higher by the end of the year.
Based on prices advertised on social media, Daxxify is still priced higher than Botox (assuming 2-to-1 units) in most practices offering it.
Don't sleep on the therapeutic payer progress. As noted on the call, some commercial payers will cover Daxxify in place of Botox for any therapeutic indication. Unlike in aesthetics where many CosmeticMDs are motivated by kickbacks from Galderma or Abbvie to cover their alimony payments, in therapeutics the doctors and payers are incentivized to provide patients the best treatment at the best price—which when it comes to neurotoxins is clearly Daxxify.
Uh huh. Daxxify units did better QoQ than Jeuveau. You're not fooling anybody anymore about your intentions here. For example, this intentionally misleading one liner you just posted:
EOLS doesn't have filler sales which suffer from worse seasonality. Daxxify grew units QoQ but revenue was impacted by the coupon. It looks like Jeuveau was down slightly on units QoQ.
Yes, that's expenses. That's good.
I guess you've never heard of seasonality and don't know that Q1 is the weakest quarter of the year. 🤦
It was an OK quarter considering. The Daxxify unit and account growth is encouraging.
Many of the practices offering Daxxify do heavily market that it is vegan. It's a strong selling point and Revance should definitely lean into it. However I think the use of the word "safe" or any allusion to these types of incidents is a very bad idea.
Where are all the "market is never wrong" folks today. 🤣
Respectfully I disagree. I used to respect jbog as well but he's since turned into clown who spins everything about RVNC as bearish. See, he told you himself. He was burned by the stock and now he hates the company. I think that's juvenile and emotional and not how a seasoned investor aspires to behave. Time will tell if he was right or just misguided.
You're pathetic jbog. Obviously that was wrong and I did buy some shares on the way down, but it's de minimis compared to the huge gains I've already realized over the years. Focus on this part of my message:
$10? Jbog, I sold a bunch of shares at $37 last year. I have made a huge amount of money on RVNC since I first owned it in 2016. Revance has been a huge money maker for those who have traded it at the right time. Evolus? Not so much. Yes I still own shares that are underwater, but it's house money. I have a negative trade-adjusted cost basis. Most people here are more concerned with whether the current share price represents a buying opportunity for future gains than whether or not they should have done something differently in the past. You were clearly burned by RVNC and now you've turned into a right RVNCQ clown who spins everything as bearish. If you're so negative why don't you short it?
The feeling is mutual iwfal. Ian is clearly a liar since he just outright lied about what Dew posted on the other board. I didn't think you were stupid but your inability to understand the difference has me second guessing that. You were also naive about double dose Jeuveau.
You are a liar and a loser Ian. I've known that for a while but now everyone can see it. You're even more unhinged than CosmeticMD, who at least is motivated by kickbacks from Galderma. What's your motive? You seem to be angry at Dew because you lost money.
I bet this WorstLuck person (who btw is the only person on this site I have muted) was buying ZM and DOCU in 2020 because "the market must be right." 😂